Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Parents or legally authorized representatives must give signed informed consent before any trial related activities are conducted~* Where required, assent of the subject will be appropriately documented prior to any study related activities~* Completion of assessments at Visit 9 (Month 120 of Study MS301 \[NCT00125164\])~Exclusion Criteria:~* Incomplete participation in MS301 (NCT00125164)~* Known or suspected allergy to the trial product (mecasermin, recombinant human IGF-1 injection) or its formulation~* Development or presence of a chronic condition except as approved by the Medical Monitor~* Pregnancy~* Any social or medical condition that, in the opinion of the investigator, would be detrimental to either the subject or the study

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- All rhIGF-1 Subjects (Type: EXPERIMENTAL): All subjects entering MS306 began recombinant human insulin-like growth factor-1 (rhIGF-1) twice a day (BID) treatment. Each subject treated in MS301 had an MS306 starting dose that was based on their dose at the completion of MS301 (i.e. subcutaneous injections of rhIGF-1 at 40, 80, or 120 micrograms \[μg\]/ kilogram \[kg\] BID).~MS301 untreated control subjects were randomised in MS306 in a 1:1 ratio to a dose of either 80 or 120 μg/kg rhIGF-1 BID.~Following Protocol Amendment 1, all subjects received either 80 or 120 μg/kg rhIGF-1 BID until the implementation of Protocol Amendment 2.~Following Protocol Amendment 2, all subjects were first switched to receive subcutaneous injections of 160 μg/kg rhIGF-1 once a day (QD), followed by individual dose-escalation first to 200 μg/kg rhIGF-1 QD and subsequently to a targeted maximum dose of 240 μg/kg rhIGF-1 QD. Subjects were treated QD until the early termination of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).